Loxo Oncology Inc (LOXO)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 125.00 / 234.93
Exchange NASDAQ
Div & Yield N.A. (N.A)
Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

When there is no real worry, stocks can keep on running, but the rampage in the Nasdaq 100 is not unlike frothy action of the past.

Biotech Movers: Loxo, NewLink, BioCryst

Biotech Movers: Loxo, NewLink, BioCryst

Loxo Oncology, NewLink Genetics and BioCryst Pharmaceuticals were among the biotech movers in premarket trading on Monday.

Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors

Loxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors

The Loxo data also represent another advance for precision cancer medicine, in which patients are treated with drugs that target specific tumor mutations, regardless of where the cancer originates.

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

Here are Friday's top research calls, including upgrades for IberiaBank and Actuant, and downgrades for Kimberly-Clark and Ionis Pharma.

Loxo Oncology Stock Sees Short Interest Make 37% Move

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 723,669 share increase in total short interest for Loxo Oncology, Inc , to 2,684,523, an increase of 36.91% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.